BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22426251)

  • 1. Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer.
    Laskey RA; Poniewierski MS; Lopez MA; Hanna RK; Secord AA; Gehrig PA; Lyman GH; Havrilesky LJ
    Gynecol Oncol; 2012 Jun; 125(3):625-30. PubMed ID: 22426251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
    Shayne M; Culakova E; Poniewierski MS; Wolff D; Dale DC; Crawford J; Lyman GH
    Cancer; 2007 Oct; 110(7):1611-20. PubMed ID: 17705197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.
    Shayne M; Crawford J; Dale DC; Culakova E; Lyman GH;
    Breast Cancer Res Treat; 2006 Dec; 100(3):255-62. PubMed ID: 16705366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol.
    Carlson JW; Fowler JM; Saltzman AK; Carter JR; Chen MD; Mitchell SK; Dunn D; Carson LF; Adcock LL; Twiggs LB
    Gynecol Oncol; 1994 Dec; 55(3 Pt 1):415-20. PubMed ID: 7530677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer?
    Kim JJ; Park JY; Kim DY; Kim JH; Kim YM; Nam JH; Kim YT
    Acta Obstet Gynecol Scand; 2010 May; 89(5):623-8. PubMed ID: 20423275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
    Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
    J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients.
    Rocconi RP; Matthews KS; Kemper MK; Hoskins KE; Barnes MN
    Gynecol Oncol; 2008 Feb; 108(2):336-41. PubMed ID: 18006047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegfilgrastim primary prophylaxis in patients with non-Hodgkin lymphoma: results from an integrated analysis.
    Pettengell R; Schwenkglenks M; Bacon P; Lawrinson S; Duehrsen U
    Hematol Oncol; 2011 Dec; 29(4):177-84. PubMed ID: 21246591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study.
    Rivera E; Haim Erder M; Fridman M; Frye D; Hortobagyi GN
    Breast Cancer Res; 2003; 5(5):R114-20. PubMed ID: 12927041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
    Lyman GH; Delgado DJ
    Cancer; 2003 Dec; 98(11):2402-9. PubMed ID: 14635075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model.
    Rivera E; Erder MH; Moore TD; Shiftan TL; Knight CA; Fridman M; Brannan C; Danel-Moore L; Hortobagyi GN;
    Cancer; 2003 Jul; 98(2):222-8. PubMed ID: 12872339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of neutropenic fever in patients receiving first-line adjuvant chemotherapy for epithelial ovarian cancer.
    Sharma S; Rezai K; Driscoll D; Odunsi K; Lele S
    Gynecol Oncol; 2006 Oct; 103(1):181-5. PubMed ID: 16574203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
    Fader AN; von Gruenigen V; Gibbons H; Abushahin F; Starks D; Markman M; Belinson J; Rose P
    Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy.
    Chia VM; Page JH; Rodriguez R; Yang SJ; Huynh J; Chao C
    Breast Cancer Res Treat; 2013 Apr; 138(2):621-31. PubMed ID: 23468242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia.
    Rondinelli PI; Ribeiro Kde C; de Camargo B
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):665-70. PubMed ID: 17023827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer.
    Eichbaum MH; Weiss LM; Bruckner T; Schneeweiss A; Sinn HP; Gebauer G; Fersis N; Kussmaul J; Sohn C
    Med Sci Monit; 2009 Apr; 15(4):CR156-63. PubMed ID: 19333199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of mortality in patients with cancer who experience febrile neutropenia.
    Lyman GH; Michels SL; Reynolds MW; Barron R; Tomic KS; Yu J
    Cancer; 2010 Dec; 116(23):5555-63. PubMed ID: 20715160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutropenic complications in advanced-stage non-Hodgkin's lymphoma: implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF).
    Bobey N; Woodman RC
    Clin Invest Med; 1998 Apr; 21(2):63-70. PubMed ID: 9562926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Patient-Generated Subjective Global Assessment (PG-SGA) as a predictor of febrile neutropenia in gynecologic cancer patients receiving combination chemotherapy: a pilot study.
    Phippen NT; Lowery WJ; Barnett JC; Hall LA; Landt C; Leath CA
    Gynecol Oncol; 2011 Nov; 123(2):360-4. PubMed ID: 21864889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.